Alere (ALR) Given Media Impact Score of 0.06
News stories about Alere (NYSE:ALR) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alere earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.0188239101541 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Alere Inc. (ALR)- Stocks having Bumpy Ride for the Day – NASDAQ Times (nasdaqtimes.com)
- Alere Announces FDA Clearance For I Influenza A & B 2 Rapid Molecular Test (nasdaq.com)
- Alere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test (streetinsider.com)
- Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test (finance.yahoo.com)
- Corporate News Blog – Alere Announces Agreement with the US Department of Justice; Settles the Investigations Concerning Previous Foreign Acquisitions (finance.yahoo.com)
Alere (NYSE:ALR) opened at 50.99 on Tuesday. The firm’s market cap is $4.47 billion. Alere has a one year low of $34.41 and a one year high of $51.00. The company’s 50-day moving average is $49.76 and its 200 day moving average is $48.26.
A number of analysts have recently commented on the company. BidaskClub lowered Alere from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Zacks Investment Research cut Alere from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $51.00 price objective on shares of Alere in a report on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $48.00.
TRADEMARK VIOLATION NOTICE: “Alere (ALR) Given Media Impact Score of 0.06” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/alere-alr-given-media-impact-score-of-0-06/1604392.html.
Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.
Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.